PCM
EXAS

Palisade Capital Management’s Exact Sciences EXAS Stock Holding History

Palisade Capital Management’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-17,000
Closed -$686K – 461
2018
Q1 		$686K Buy
+17,000
New +$829K 0.02% 364

Other funds holding EXAS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Palisade Capital Management's EXAS Position: Q2 2018 in Review

Palisade Capital Management sold out of Exact Sciences (EXAS) in Q2 2018, closing a stake of 17,000 shares — an estimated $686K sold.

Palisade Capital Management first reported a position in EXAS in Q1 2018 and held it in 1 quarter. The position peaked at $686K in Q1 2018. 349 funds tracked by Wall St. Rank hold EXAS as of Q2 2018.

  • Palisade Capital Management reported no remaining Exact Sciences position as of Q2 2018 after selling out during the quarter.
  • Palisade Capital Management sold 17,000 Exact Sciences shares in Q2 2018, an estimated $686K.
  • Palisade Capital Management first reported a position in Exact Sciences in Q1 2018 and held it in 1 quarter.
  • Palisade Capital Management's Exact Sciences position peaked at $686K in Q1 2018.
  • 349 funds tracked by Wall St. Rank held Exact Sciences as of Q2 2018.

Based on Palisade Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.